[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @kainvests Kai invests Kai invests posts on X about $iova, $nbis, cart, mckesson the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1964979414695075840/interactions)  - X Week XXXXX +546% ### Mentions: XX [#](/creator/twitter::1964979414695075840/posts_active)  - X Week XX +475% ### Followers: XX [#](/creator/twitter::1964979414695075840/followers)  - X Week XX +122% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1964979414695075840/influencer_rank)  ### Social Influence [#](/creator/twitter::1964979414695075840/influence) --- **Social category influence** [stocks](/list/stocks) XXXXX% [finance](/list/finance) XXX% **Social topic influence** [$iova](/topic/$iova) #7, [$nbis](/topic/$nbis) #263, [cart](/topic/cart) 4.35%, [mckesson](/topic/mckesson) 4.35%, [a very](/topic/a-very) XXXX% **Top accounts mentioned or mentioned by** [@newstart2024](/creator/undefined) [@iovancebio](/creator/undefined) [@theraymyers](/creator/undefined) [@kaisaysiovancebiotherapeuticsiovasavinglivesonabeautifulhardfoughtpath0e16839a8f9f](/creator/undefined) [@biotechscanner](/creator/undefined) [@deucecabooseski](/creator/undefined) [@pepemoonboy](/creator/undefined) [@accountingds](/creator/undefined) [@apextradez](/creator/undefined) [@yodastockinvest](/creator/undefined) [@dividenddudex](/creator/undefined) [@ghoutanews](/creator/undefined) [@toptechstocksus](/creator/undefined) **Top assets mentioned** [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [Nebius Group N.V. Class A Ordinary Shares (NBIS)](/topic/$nbis) [McKesson Corporation (MCK)](/topic/mckesson) ### Top Social Posts [#](/creator/twitter::1964979414695075840/posts) --- Top posts by engagements in the last XX hours "What's the difference between CAR-T and TIL therapies A video: A thread: #IOVA" [X Link](https://x.com/kainvests/status/1978353407162224856) [@kainvests](/creator/x/kainvests) 2025-10-15T06:53Z XX followers, XXX engagements "#1 Most people focus on the complexity and cost of delivering a TIL solution and yet CAR-T has always been complex and expensive: CAR-T is also highly personalised and costs between $400000$700000 while TIL costs $500000. $IOVA" [X Link](https://x.com/kainvests/status/1978353785522028774) [@kainvests](/creator/x/kainvests) 2025-10-15T06:54Z XX followers, XXX engagements "$IOVA Most of us are biased toward a happy ending with Iovance. Shall we talk about whats likely to happen if the NSCLC data simply isnt good enough Do we foresee a dramatic dump and then a bump as happened with Replimune We need to be prepared for whatever happens" [X Link](https://x.com/kainvests/status/1978180550402748459) [@kainvests](/creator/x/kainvests) 2025-10-14T19:26Z XX followers, XXX engagements "@TheRayMyers $NBIS and $IOVA; already have" [X Link](https://x.com/kainvests/status/1978324196561154196) [@kainvests](/creator/x/kainvests) 2025-10-15T04:56Z XX followers, XXX engagements "#4 CAR-T can't compete with TIL therapy for solid tumors. CAR-T dominate blood cancer (leukemia myeloma lymphoma etc) but don't work in solid tumors. CAR-T is a great example of a highly complex treatment becoming profitable over time" [X Link](https://x.com/kainvests/status/1978360489928245420) [@kainvests](/creator/x/kainvests) 2025-10-15T07:21Z XX followers, XX engagements "#5 TIL therapy true competitors are immune checkpoint inhibitors (the famous pembrolizumab) which are the 1st line standard and potentially TCR-T which are years behind compared to TIL. Notably Iovance is already working with Merck to combine pembrolizumab and TIL" [X Link](https://x.com/kainvests/status/1978361346853949904) [@kainvests](/creator/x/kainvests) 2025-10-15T07:24Z XX followers, XX engagements "$IOVA What's most likely: a BO or a partnership A partnership. Why Iovance is actively expanding commercial partnerships to increase patient access (e.g. with specialty pharmacies like Biologics by McKesson) and authorised treatment centres" [X Link](https://x.com/kainvests/status/1977742093385642328) [@kainvests](/creator/x/kainvests) 2025-10-13T14:23Z XX followers, XXX engagements "Hi @newstart_2024. I was very moved by your post on TIL therapy. Thanks for that. Many of us are investing in $IOVA to help make it happen and hopefully get some returns. I thought you may want to know of its existence and spread the word. We have binary catalysts coming" [X Link](https://x.com/kainvests/status/1977994478620397923) [@kainvests](/creator/x/kainvests) 2025-10-14T07:06Z XX followers, XXX engagements "Are you in $NBIS but not in $IOVA You may want to look into it. 😉" [X Link](https://x.com/kainvests/status/1978324088599744989) [@kainvests](/creator/x/kainvests) 2025-10-15T04:56Z XX followers, XXX engagements "#6 And guess what Merck's key patents on Keytruda (pembrolizumab) are set to expire in 2028 but they will have exclusivity until 2030/2031. Merck here is a competitor but it has wisely also chosen to be an ally: these are TILVANCE-301 and IOV-COM-202. BO coming Partnership" [X Link](https://x.com/kainvests/status/1978362212495380809) [@kainvests](/creator/x/kainvests) 2025-10-15T07:28Z XX followers, XX engagements "$IOVA Iovance said at Wells Fargo that they will have a third party validate the NSCLC data. Someone made a very intelligent observation on StockTwits/IOVA yesterday. Why would they bother to have a third party validate bad data" [X Link](https://x.com/kainvests/status/1976183753916678196) [@kainvests](/creator/x/kainvests) 2025-10-09T07:11Z XX followers, XXX engagements "@apex_tradez My 31000 shares are my most precious treasure. Best of luck fellow IOVA investor" [X Link](https://x.com/kainvests/status/1979093101126771109) [@kainvests](/creator/x/kainvests) 2025-10-17T07:52Z XX followers, XXX engagements "@YodaStockInvest $IOVA in a few months and for a good cause 😉" [X Link](https://x.com/kainvests/status/1978323922606064081) [@kainvests](/creator/x/kainvests) 2025-10-15T04:55Z XX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@kainvests Kai invests
Kai invests posts on X about $iova, $nbis, cart, mckesson the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +546%
Mentions: XX #
- X Week XX +475%
Followers: XX #
- X Week XX +122%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks XXXXX% finance XXX%
Social topic influence $iova #7, $nbis #263, cart 4.35%, mckesson 4.35%, a very XXXX%
Top accounts mentioned or mentioned by @newstart2024 @iovancebio @theraymyers @kaisaysiovancebiotherapeuticsiovasavinglivesonabeautifulhardfoughtpath0e16839a8f9f @biotechscanner @deucecabooseski @pepemoonboy @accountingds @apextradez @yodastockinvest @dividenddudex @ghoutanews @toptechstocksus
Top assets mentioned Iovance Biotherapeutics, Inc. Common Stock (IOVA) Nebius Group N.V. Class A Ordinary Shares (NBIS) McKesson Corporation (MCK)
Top Social Posts #
Top posts by engagements in the last XX hours
"What's the difference between CAR-T and TIL therapies A video: A thread: #IOVA"
X Link @kainvests 2025-10-15T06:53Z XX followers, XXX engagements
"#1 Most people focus on the complexity and cost of delivering a TIL solution and yet CAR-T has always been complex and expensive: CAR-T is also highly personalised and costs between $400000$700000 while TIL costs $500000. $IOVA"
X Link @kainvests 2025-10-15T06:54Z XX followers, XXX engagements
"$IOVA Most of us are biased toward a happy ending with Iovance. Shall we talk about whats likely to happen if the NSCLC data simply isnt good enough Do we foresee a dramatic dump and then a bump as happened with Replimune We need to be prepared for whatever happens"
X Link @kainvests 2025-10-14T19:26Z XX followers, XXX engagements
"@TheRayMyers $NBIS and $IOVA; already have"
X Link @kainvests 2025-10-15T04:56Z XX followers, XXX engagements
"#4 CAR-T can't compete with TIL therapy for solid tumors. CAR-T dominate blood cancer (leukemia myeloma lymphoma etc) but don't work in solid tumors. CAR-T is a great example of a highly complex treatment becoming profitable over time"
X Link @kainvests 2025-10-15T07:21Z XX followers, XX engagements
"#5 TIL therapy true competitors are immune checkpoint inhibitors (the famous pembrolizumab) which are the 1st line standard and potentially TCR-T which are years behind compared to TIL. Notably Iovance is already working with Merck to combine pembrolizumab and TIL"
X Link @kainvests 2025-10-15T07:24Z XX followers, XX engagements
"$IOVA What's most likely: a BO or a partnership A partnership. Why Iovance is actively expanding commercial partnerships to increase patient access (e.g. with specialty pharmacies like Biologics by McKesson) and authorised treatment centres"
X Link @kainvests 2025-10-13T14:23Z XX followers, XXX engagements
"Hi @newstart_2024. I was very moved by your post on TIL therapy. Thanks for that. Many of us are investing in $IOVA to help make it happen and hopefully get some returns. I thought you may want to know of its existence and spread the word. We have binary catalysts coming"
X Link @kainvests 2025-10-14T07:06Z XX followers, XXX engagements
"Are you in $NBIS but not in $IOVA You may want to look into it. 😉"
X Link @kainvests 2025-10-15T04:56Z XX followers, XXX engagements
"#6 And guess what Merck's key patents on Keytruda (pembrolizumab) are set to expire in 2028 but they will have exclusivity until 2030/2031. Merck here is a competitor but it has wisely also chosen to be an ally: these are TILVANCE-301 and IOV-COM-202. BO coming Partnership"
X Link @kainvests 2025-10-15T07:28Z XX followers, XX engagements
"$IOVA Iovance said at Wells Fargo that they will have a third party validate the NSCLC data. Someone made a very intelligent observation on StockTwits/IOVA yesterday. Why would they bother to have a third party validate bad data"
X Link @kainvests 2025-10-09T07:11Z XX followers, XXX engagements
"@apex_tradez My 31000 shares are my most precious treasure. Best of luck fellow IOVA investor"
X Link @kainvests 2025-10-17T07:52Z XX followers, XXX engagements
"@YodaStockInvest $IOVA in a few months and for a good cause 😉"
X Link @kainvests 2025-10-15T04:55Z XX followers, XXX engagements